Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Urban Simoncic

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Genitourinary Cancer|August 17, 2014
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastasesUrban Simoncic, Scott Perlman, Glenn Liu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2016
Analysis of pairwise correlations in multi-parametric PET/MR data for biological tumor characterization and treatment individualization strategiesSara Leibfarth, Urban Simoncic, David Mönnich, et al.
Radiology and Oncology|February 3, 2016
Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CTSebastijan Rep, Luka Lezaic, Tomaz Kocjan, et al.
Radiology and Oncology|July 30, 2020
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumabDamijan Valentinuzzi, Martina Vrankar, Nina Boc, et al.
Medical Physics|March 21, 2017
Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patientsUrban Simoncic, Sara Leibfarth, Stefan Welz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2011
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malateGlenn Liu, Robert Jeraj, Matt Vanderhoek, et al.
Pharmaceuticals (Basel, Switzerland)|December 31, 2020
Selection of the First <sup>99m</sup>Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized CandidatesMelpomeni Fani, Viktoria Weingaertner, Petra Kolenc Peitl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 15, 2023
Comparison of 99mTc radiolabeled somatostatin antagonist with [<sup>68</sup> Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumorMarta Opalinska, Luka Lezaic, Clemens Decristoforo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a <sup>99m</sup>Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical TrialAlicja Hubalewska-Dydejczyk, Clemens Decristoforo, Renata Mikolajczak, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Genitourinary Cancer|August 17, 2014
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastasesUrban Simoncic, Scott Perlman, Glenn Liu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2016
Analysis of pairwise correlations in multi-parametric PET/MR data for biological tumor characterization and treatment individualization strategiesSara Leibfarth, Urban Simoncic, David Mönnich, et al.
Radiology and Oncology|February 3, 2016
Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CTSebastijan Rep, Luka Lezaic, Tomaz Kocjan, et al.
Radiology and Oncology|July 30, 2020
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumabDamijan Valentinuzzi, Martina Vrankar, Nina Boc, et al.
Medical Physics|March 21, 2017
Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patientsUrban Simoncic, Sara Leibfarth, Stefan Welz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2011
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malateGlenn Liu, Robert Jeraj, Matt Vanderhoek, et al.
Pharmaceuticals (Basel, Switzerland)|December 31, 2020
Selection of the First <sup>99m</sup>Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized CandidatesMelpomeni Fani, Viktoria Weingaertner, Petra Kolenc Peitl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 15, 2023
Comparison of 99mTc radiolabeled somatostatin antagonist with [<sup>68</sup> Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumorMarta Opalinska, Luka Lezaic, Clemens Decristoforo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a <sup>99m</sup>Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical TrialAlicja Hubalewska-Dydejczyk, Clemens Decristoforo, Renata Mikolajczak, et al.
Pageof 2